Print

Covidien plc (COV) Opens Patient Enrollment for SWIFT PRIME Acute Ischemic Stroke Study  
1/14/2013 9:24:11 AM

MANSFIELD, Mass.--(BUSINESS WIRE)--Covidien (NYSE:COV), a leading global provider of healthcare products, today announced the launch of a new study, SWIFT PRIME, which enrolled its first patient at the University at Buffalo. The new multi-center, randomized controlled trial will be one of the largest global studies to examine the adjunctive use of mechanical thrombectomy during the early stages of acute ischemic stroke onset. Acute ischemic stroke occurs when a clot in a blood vessel blocks blood supply to the brain. According to the American Heart Association, acute ischemic stroke is the leading cause of disability and the fourth most common cause of death in the United States.
//-->